Boost your CPD points and test your knowledge on recent updates to medicines and clinical and practice guidelines.

After completing the Annual Gold Questionnaire 2024, pharmacists should be able to:

  • Recognise accurate and current health information
  • Use readily available information sources to access and select relevant and up-to-date clinical and practice-based information
  • Demonstrate knowledge of current and evidence-based information and use it to improve the quality use of medicines.

Competency standards (2016) addressed: 1.1, 1.2, 1.3, 1.4, 1.5, 3.1, 3.5, 5.3

Accreditation number: CONL2425

Accreditation expiry: 30/09/2025

The key details

  • There are 25 questions, all are compulsory.
  • Each question has ONE correct answer and FOUR distractors.
  • See list of suggested references for those you may need to refer to when completing
    the questionnaire.
  • Please submit answers at my.psa.org.au/s/education-catalogue selecting ‘Annual Gold Questionnaire’ under ‘Select a Type or Delivery Method’.
  • Answers MUST be submitted online by 30 September 2025.
  • The pass mark is 75%, or 19 correct responses out of 25 questions.

This article is accredited for group 2 CPD credits. Click submit answers to complete the quiz and automatically record CPD against your record.

SUBMIT ANSWERS

If you do get an enrolment error, please click here

AGQ 2024 Contributors

Alexandra Bradshaw BPharm (Hons), MPS

Affiliate Associate Professor Juanita Breen PhD, MSc, BPharm, MPS, GradDipCommPracPharm

Caitlin Davies BPharm, AACPA, MPS

Han-Fang Hsiao-Telford BPharm (Hons), BPharmSci, MPS

Lily Pham BPharm, MPhil, GradCertEdStud (Higher Ed), FHEA, MPS, MSHP

Alyssa Pisano BPharm (Hons)

Karla Wright BPharm (Hons), AACPA, GradDipClinPharm, MACP JP(Qual), MPS

Suggested References

To answer these questions, you may need to refer to the following references:

Disclaimer

The Pharmaceutical Society of Australia has made every effort to ensure that, at the date of publication, the document is free from errors and that advice and information drawn upon have been provided in good faith. Neither the Pharmaceutical Society of Australia nor any person or organisation associated with the preparation of this document accepts liability for any loss which a user of this document may suffer as a result of reliance on the document and in particular for:
  • use of the document for a purpose for which it was not intended
  • any errors or omissions in the document
  • any inaccuracy in the information or data on which the document is based or which are contained in the document
  • any interpretations or opinions stated in, or which may be inferred from, the document.
© Pharmaceutical Society of Australia 2024
This publication contains material that has been provided by the Pharmaceutical Society of Australia (PSA), and may contain material provided by the Commonwealth and third parties. Copyright in material provided by the Commonwealth or third parties belongs to them. PSA owns the copyright in the publication as a whole and all material in the publication that has been developed by PSA. In relation to PSA owned material, no part may be reproduced by any process except in accordance with the provisions of the Copyright Act 1968 (Cth), or the written permission of PSA. Requests and inquiries regarding permission to use PSA material should be addressed to: Pharmaceutical Society of Australia, PO Box 42, Deakin West ACT 2600. Where you would like to use material that has been provided by the Commonwealth or third parties, contact them directly.